| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10032358 | HBV | ENSG00000197405.8 | protein_coding | C5AR1 | No | No | 728 | P21730 |
| TVIS30020495 | HIV | ENSG00000197405.8 | protein_coding | C5AR1 | No | No | 728 | P21730 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | C5AR1 |
|---|---|
| DrugBank ID | DB15011 |
| Drug Name | Avacopan |
| Target ID | BE0010095 |
| UniProt ID | P21730 |
| Regulation Type | antagonist |
| PubMed IDs | 24179165; 27768695; 29867214 |
| Citations | Xiao H, Dairaghi DJ, Powers JP, Ertl LS, Baumgart T, Wang Y, Seitz LC, Penfold ME, Gan L, Hu P, Lu B, Gerard NP, Gerard C, Schall TJ, Jaen JC, Falk RJ, Jennette JC: C5a receptor (CD88) blockade protects against MPO-ANCA GN. J Am Soc Nephrol. 2014 Feb;25(2):225-31. doi: 10.1681/ASN.2013020143. Epub 2013 Oct 31.@@Bekker P, Dairaghi D, Seitz L, Leleti M, Wang Y, Ertl L, Baumgart T, Shugarts S, Lohr L, Dang T, Miao S, Zeng Y, Fan P, Zhang P, Johnson D, Powers J, Jaen J, Charo I, Schall TJ: Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study. PLoS One. 2016 Oct 21;11(10):e0164646. doi: 10.1371/journal.pone.0164646. eCollection 2016.@@Liu H, Kim HR, Deepak RNVK, Wang L, Chung KY, Fan H, Wei Z, Zhang C: Orthosteric and allosteric action of the C5a receptor antagonists. Nat Struct Mol Biol. 2018 Jun;25(6):472-481. doi: 10.1038/s41594-018-0067-z. Epub 2018 Jun 4. |
| Groups | Approved; Investigational |
| Direct Classification | 1-benzoylpiperidines |
| SMILES | CC1=CC=C(NC(=O)[C@H]2CCCN([C@H]2C2=CC=C(NC3CCCC3)C=C2)C(=O)C2=C(F)C=CC=C2C)C=C1C(F)(F)F |
| Pathways | |
| PharmGKB | |
| ChEMBL | CHEMBL3989871 |
